BCL2L1 and colorectal carcinoma: In this case, using higher doses of less orally bioavailable BCL-XL inhibitors would offer potential to improve treatment efficacy but more so, identifying kinase targets whose inhibition could synergize with BCL-XL targeting could provide novel strategies to target CRC tumors.